Class II · Moderate risk
Ipamorelin 9 mg vial Lyophilized 1109 East Hallandale Beach Blvd. Hallandale Beach
Lack of assurance of sterility.
FDA Drug Recalls
1,590 recalls, newest first
Class II · Moderate risk
Methylcobalamin 10 mg vial Lyophilized 1109 East Hallandale Beach Blvd. Hallandale Beach
Lack of assurance of sterility.
Class II · Moderate risk
Ipamorelin 3 mg Lyophilized 1 vial 1109 East Hallandale Beach Blvd. Hallandale Beach
Lack of assurance of sterility.
Class II · Moderate risk
Human Chorionic Gonadotropin 6000 IU Vial Lyophilized 1109 East…
Lack of assurance of sterility.
Class II · Moderate risk
Human Chorionic Gonadotropin 4000 IU Vial Lyophilized 1109 East…
Lack of assurance of sterility.
Class II · Moderate risk
Human Chorionic Gonadotropin 2500 IU Vial Lyophilized 1109 East…
Lack of assurance of sterility.
Class II · Moderate risk
Human Chorionic Gonadotropin 20000 IU Vial Lyophilized 1109 East…
Lack of assurance of sterility.
Class II · Moderate risk
Human Chorionic Gonadotropin 11000 IU Vial Lyophilized 1109 East…
Lack of assurance of sterility.
Class II · Moderate risk
Human Chorionic Gonadotropin 5000 IU Vial Lyophilized 1109 East…
Lack of assurance of sterility.
Class III · Low risk
Atorvastatin Calcium tablets
Failed Impurities/Degradation Specifications - OOS was observed for ATV Cyclo FP Impurity and Total Degradation Impurities tested at the 18 month stability time point in Atorvastatin Calcium Tablets 40 mg 500 tablets.
Class II · Moderate risk
Doxycycline Hyclate Tablets
Failed Dissolution Specifications: Out of specification result for the dissolution test.
Class II · Moderate risk
Lidocaine 2.5% and Prilocaine Cream
Failed Impurities/Degredation Specifications: Out of Specification results for an unknown impurity was found during routine stability testing at 12 months.
Class III · Low risk
Levofloxacin Injection in 5% Dextrose
Superpotent Drug: High out of specification results for levofloxacin resulting in increased concentration of solution.
Class III · Low risk
Levofloxacin Injection in 5% Dextrose
Superpotent Drug: High out of specification results for levofloxacin resulting in increased concentration of solution.
Class III · Low risk
Levofloxacin Injection in 5% Dextrose
Superpotent Drug: High out of specification results for levofloxacin resulting in increased concentration of solution.
Class II · Moderate risk
Valsartan/HCTZ 320/25mg Tablets
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Class II · Moderate risk
Valsartan/HCTZ 160/25mg Tablets
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Class II · Moderate risk
Valsartan/HCTZ 160/12.5 mg Tablets
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Class II · Moderate risk
Doxycycline Hyclate Tablets
Failed Dissolution Specifications
Class II · Moderate risk
Valsartan 320 mg tablets
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Class II · Moderate risk
Valsartan 320 mg tablets
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Class II · Moderate risk
Valsartan 80 mg tablets
CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Class III · Low risk
Moxifloxacin Ophthalmic Solution USP
Failed Impurities/Degradation Specifications: An out-of-specification result in the related substance test during three month long-term stability study.
Class III · Low risk
Testosterone 200 mg Pellet
Labeling: Incorrect or Missing Lot and/or Exp Date: Incorrect expiration date on label
Class II · Moderate risk
Valsartan tablets 160 mg
Carcinogen impurity detected in API used to manufacture drug product.